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Toronto, Ontario, CanadaCardiac stem cell therapy has received significant attention
as a potential biointervention to ameliorate post–myocardial
infarction congestive heart failure. Recent prospective
randomized clinical trials have provided some evidence
showing potential efficacy, although the benefit obtained
has been relatively small.1 Thus far, the majority of the ev-
idence suggests that adult stem cells do not cause de novo
cardiomyogenesis on a large and reproducible extent.
Some have proposed that using embryonic stem cells, which
clearly have cardiomyogenic potential, could enhance the
beneficial impact of stem cell therapy. Indeed, this may be
the case. However, undifferentiated embryonic stem cells
are plagued with the potential for teratoma formation.2 To
date, this concern has not been an issue for adult-derived
stem cells.
We3 recently described the substantial functional benefit
of transplanting genetically engineered adult-derived mes-
enchymal stem cells (MSCs) overproducing stem cell factor
(SCF) when transplanted immediately after myocardial in-
farction. Pressure–volume loop analysis during inferior
vena caval occlusion showed a 1.9-fold increase (P <
0.001) in the slope of preload-recruitable stroke work in
animals that received MSCs genetically enhanced with
SCF (MSC–SCF) compared with those that received only
MSCs. The improvement in end-systolic elastance was sim-
ilar to the improvement in preload-recruitable stroke work.
Thus, independent of preload, MSC–SCF provided superior
functional benefit. In addition, the left ventricular volume
was 0.6-fold smaller (P<.01) in the MSC–SCF group com-
pared with the MSC-alone group. These benefits were
clearly independent of neo-cardiomyogenesis and likely
represent the paracrine influence of the transplanted cells
on progenitor cell recruitment and enhancement of
endogenous repair mechanism.3
Here we report extensive tumor formation in 4 of 20 mice
treated with intramyocardial MSC–SCF. In the first mouse,
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transplantation. Necropsy showed an intracardiac mass
that had invaded the chest wall with gross tumor burden vis-
ible in multiple locations (Figure 1). Histologically, this tu-
mor was a soft tissue sarcoma with greater than 10 mitotic
figures per high-power field (Figure 2, A). The tumor was
clearly not of thymic origin and appeared to diffusely infil-
trate themyocardium (Figure 2,B). It also had both a necrotic
core (Figure 2, C) and clear evidence of blood vessel inva-
sion (Figure 2, D). All metastases were in soft tissues and
no evidence of pulmonary, skeletal, or cerebral metastases
could be found. The tumor stained strongly with an antibody
against a-smooth muscle actin, suggesting that it was a fibro-
sarcoma. Altogether, the final pathologic diagnosis was
grade IV fibrosarcoma with hematogenous spread. These
findings prompted more careful analysis of the histologic
specimens of the 19 other animals that had already been sac-
rificed at day 28 for morphologic and functional evaluation.
An additional 3 animals had intramyocardial fibrosarcomas
detected. These mice did not have evidence for metastatic
spread.
The MSCs used for these studies were in culture between
20 and 45 passages. They had stable expression of CD81 and
stem cell antigen-1 but did not express c-kit (SCF receptor),
CD34, CD45, or CD31.3 None of the 16 mice in the MSC-
alone group had tumor formation. In parallel studies looking
at the impact of MSCs and MSCs engineered to overexpress
tissue inhibitors of matrix metalloproteinase-3, none of the
FIGURE 1. Extensive soft tissue metastatic spread of an intracardiac tu-
mor (white arrows), which invades the chest well, is demonstrated here.
This tumor was discovered 89 days after cell transplantation into the heart
(arrow) in the only mouse that was not sacrificed at the end of the previous
study.3rgery c November 2008
Brief CommunicationsFIGURE 2. Histologic study of the tumor (T) shows a very aggressive fibrosarcoma with a high mitotic index (A), with extensive intramyocardial (M)
invasion (B), a necrotic core (red arrow) attesting to rapid growth (C), and hematogenous dissemination. The green arrow points to a blood vessel (D).total 90 mice have shown macroscopic evidence of malig-
nancy using the same MSC line (unpublished data). The
vector carrying the SCF transgene was pCDNA3 and trans-
fection was achieved using a lipid-based technique. Stable
transfectants were selected and maintained using 200 mg/
mL G418-spiked Iscove Modified Dulbecco’s Medium
over 5 additional passages. Other studies have documented
the potential for MSC transformation using genetic manipu-
lation of the Wnt pathway.4 However, MSCs up to passage
25, have been clearly demonstrated not to develop cytoge-
netic abnormalities and not to undergo malignant transfor-
mation in vitro.5
Our study is the first to clearly document malignant
transformation of MSCs after genetic manipulation. Al-
though the cells had been in culture for a prolonged period,
malignant transformation has not been observed in MSC-
alone groups or in MSCs transiently transfected with the
tissue inhibitors of matrix metalloproteinase-3 gene. Given
that G418 is routinely used for selection of stable transfec-
tant in neomycin-gene carrying plasmids without a reported
case of malignant transformation to our knowledge, we are
led to believe that the combination of MSCs with SCFThe Journal of Thoracic and Coverexpression may have increased the predisposition to
malignant transformation in adult-derived MSCs. These
findings raise significant concerns for attempts at gene en-
hancement of adult-derived stem cells for myocardial re-
pair. This conclusion comes with a critical caveat that the
malignant transformation was caused by the specific com-
bination of techniques that we used to generate our cell
line.
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